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The aim of this study was to evaluate the WIDER I system for susceptibility testing of
Haemophilus influenzae and Streptococcus pneumoniae. MICs of 12 antimicrobials against 42
H. influenzae and 58 S. pneumoniae strains were determined using 1W MIC panels and
compared with those obtained by microdilution. Overall essential agreements were
>99%. Very major errors were not detected. Major errors occurred with ampicillin (1.7%
H. influenzae). Minor errors were 2.3% (amoxicillin–clavulanate, cefuroxime, chloram-
phenicol), 7.1% (ampicillin) and 16.7% (clarithromycin) for H. influenzae, and 1.7%
(chloramphenicol, erythromycin, meropenem), 3.4% (amoxicillin–clavulanate, cefurox-
ime, tetracycline) and 8.6% (levofloxacin) for S. pneumoniae. The WIDER I system is a
reliable method for susceptibility testing of H. influenzae and S. pneumoniae.
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Haemophilus influenzae and Streptococcus pneumoniae
are important causes of community-acquired
respiratory tract infections. Routine susceptibility
testing of antimicrobial agents against these fasti-
dious microorganisms is recommended because of
their variable susceptibility to b-lactams (penicil-
lins and cephalosporins), macrolides, chloramphe-
nicol, rifampicin, quinolones, and co-trimoxazole
[1–4]. Semi-automated systems developed for bac-
terial identification and sometimes also for sus-
ceptibility testing detect bacterial growth using
turbidimetric, radiometric or fluorometric meth-
ods [5–8]. Most of these systems are not standar-
dized to evaluate the susceptibility of H. influenzae
and S. pneumoniae to antimicrobial agents.
Image analysis technology has been applied to
certain devices that analyze inhibition zones
obtained by disk susceptibility test methods [9–
11]. WIDER I (Francisco Soria Melguizo, SA,
Madrid, Spain) is a new computer-assisted
image-processing system developed for bacterial
identification and susceptibility testing that has
been adapted to read MicroScan panels (Dade
MicroScan, West Sacrament, CA, USA) [12]. After
24 h of incubation, the image of the panel is digiti-
zed by a video camera (Hitachi KP-D50 color,
Crofton, MD, USA). The software included in the
computerized module analyzes the images from
the respective wells, and generates parameters
related to color changes (bacterial identification)
and bacterial growth (antimicrobial susceptibility).
The objective of this study was to evaluate the
reliability of the WIDER I system for susceptibility
testing of clinical isolates of H. influenzae and S.
pneumoniae.
Forty-two and 58 non-consecutive isolates of
H. influenzae and S. pneumoniae, respectively,
collected from clinically valuable respiratory sam-
ples at the Department of Clinical Microbiology,
University Hospital Virgen Macarena of Seville,
Spain, between 1998 and 1999, were evaluated.
The isolates are representative of all the different
antimicrobial susceptibility patterns (b-lactams,
quinolones, macrolides, chloramphenicol, rifam-
picin, and tetracycline) observed during this
period. Prior to susceptibility testing, the isolates
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were subcultured twice on chocolate agar (H.
influenzae) or Mueller–Hinton agar supplemented
with 5% sheep blood (S. pneumoniae) (Biomedics,
Francisco Soria Melguizo, SA). H. influenzae ATCC
49247 and S. pneumoniae ATCC 49619 were used as
control strains for susceptibility testing.
Isolates of H. influenzae were identified by
requirements for X and V factors (Mast Diagnostic,
Merseyside, UK) and the API NH system (bioMe´r-
ieux, SA, Marcy-I’E´toile, France). Isolates of S.
pneumoniae were identified by the API Streptococ-
cus system (bioMe´rieux), susceptibility to optochin
(Oxoid, Madrid, Spain), solubility in 10% sodium
deoxycholate (BBL Becton Dickinson, Madrid,
Spain), and agglutination with specific antiserum
(Phadebact Boule, Madrid, Spain).
Pre-dried WIDER 1W MIC panels (1W panels;
Dade MicroScan), containing lyophilized antimi-
crobial agents, were used for susceptibility testing
of H. influenzae and S. pneumoniae isolates. Bacterial
suspensions of H. influenzae and S. pneumoniae
were prepared in Haemophilus test medium
(HTM; Francisco Soria Melguizo, SA) and in
cation-adjusted Mueller–Hinton broth supple-
mented with 3% lyzed horse blood (LHB; Fran-
cisco Soria Melguizo, SA), respectively, with the
optical density adjusted to 0.15–0.2 units, mea-
sured at 540 nm (108 cfu/mL). Panels were inocu-
lated using an inoculator device (Francisco Soria
Melguizo, SA), following the manufacturer’s
instructions. Panels were incubated at 37 8C for
20 h in an atmosphere without CO2.
Microdilution in HTM or LHB was used as a
reference method, according to the National Com-
mittee for Clinical Laboratory Standards (NCCLS)
guidelines [13,14]. Amoxicillin, ampicillin, cefota-
xime, cefuroxime, chloramphenicol, erythromycin,
penicillin, rifampicin, sulfamethoxazole, tetracy-
cline, trimethoprim and vancomycin were obtained
from Sigma (Madrid, Spain), meropenem from
Zeneca (Madrid, Spain), clarithromycin and levo-
floxacin from Roussel Uclaf (Paris, France), and
clavulanic acid from SmithKline Beecham (Madrid,
Spain). The concentration ranges of antimicrobials
were the same as those in the 1W panels.
Minimal inhibitory concentrations (MICs)
obtained by the WIDER I system using 1W panels
were considered to agree with those obtained by
the reference method when they differed by 1
dilution steps. Discrepancies in the clinical cate-
gories, established according to the NCCLS break-
points, were evaluated by calculating three types
of error: very major or false susceptibility (suscep-
tible by WIDER I system and resistant by micro-
dilution), major or false resistance (resistant by
WIDER I system and susceptible by microdilution),
and minor (either susceptible or resistant by one
method, and intermediate by the other one).
According to the breakpoints defined by the
NCCLS, more than 95% of the isolates of H.
influenzae tested were susceptible to amoxicillin–
clavulanate, cefotaxime, chloramphenicol, cipro-
floxacin, levofloxacin, meropenem, rifampicin,
and tetracycline, whereas the susceptibility to clar-
ithromycin, cefuroxime, ampicillin and co-trimox-
azole ranged from 86.7% (clarithromycin) to 40.9%
(co-trimoxazole). In contrast, for S. pneumoniae, the
percentage of isolates susceptible to antimicrobial
agents was more variable, ranging from 96.5%
(rifampicin) to 36.8% (co-trimoxazole).
The susceptibility results generated by the
WIDER I system for H. influenzae and S. pneumoniae
isolates agreed closely with those obtained by the
reference method (overall essential agreement
greater than 99.5%) (Tables 1 and 2). The concor-
dance (essential agreement) between the MICs of
the antimicrobials tested with both methods ran-
ged from 97.6% to 100% for H. influenzae (Table 1)
and from 98.3% to 100% for S. pneumoniae (Table 2).
These results are comparable to those observed in
other studies performed with MICroSTREP panels
[15] and with PASCO Strep Plus panels [16]. In
contrast, the agreements between the MICs of
penicillin, cefotaxime and co-trimoxazole against
S. pneumoniae determined by the WIDER I system
and by microdilution were slightly higher (100%
for penicillin and cefotaxime, and 98.3% for co-
trimoxazole) than those obtained in the study
performed by Jorgensen et al. with the ViteK 2
system (89.8% for penicillin, 96.6% for cefotaxime,
and 89.7% for co-trimoxazole) [17].
Analysis of discrepancies in the clinical cate-
gories for the antimicrobials tested against H.
influenzae and S. pneumoniae revealed no very
major errors (Tables 1 and 2). Major errors were
detected only with ampicillin (1.7%) for H. influ-
enzae. Minor errors were more frequent, essentially
with clarithromycin (16.7%) for H. influenzae
(Table 1). The high percentage of minor errors
observed for clarithromycin may be attributable
to the values close to MIC90s (16 mg/L) and the
breakpoint defined by the NCCLS (16 mg/L for
the intermediate category). For S. pneumoniae,
major errors were not detected. Minor errors were
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low and distributed as follows: for chlorampheni-
col, erythromycin and meropenem, 1.7%; for
amoxicillin–clavulanate, cefuroxime and tetracy-
cline, 3.4%; and for levofloxacin, 8.6%.
The WIDER I system offers a high degree of
flexibility, because the results of susceptibility
testing may be interpreted by the expert software
or may be modified according to criteria defined
by the microbiologist. A major limitation of the
WIDER I system is the overnight incubation neces-
sary to read the 1W panels. Rapid generation of
MIC results may decrease the rates of morbidity
and mortality [18] and provide economic benefits,
increasing the cost-effectiveness [19]. Further stu-
dies of the WIDER I system should include the
assessment of the possibility of reducing the per-
iod of incubation of panels, ideally from 24 to 8 h.
We conclude that the WIDER I system is a
reliable method for routine susceptibility testing
of H. influenzae and S. pneumoniae. Additional
Table 1 Distribution of the differences in the MICs of 12 antimicrobial agents against 42 strains of H. influenzae, and
discrepancies in the clinical categories using the WIDER I system and microdilution (reference method)
% isolates for which the differences in the MICs are % Errors
Antimicrobial
agents  2 1 0 þ1 þ 2
% Agreement
(1 log2) Minor Major
AMX/CLV 2.4 2.4 81.0 14.3 0.0 97.6 2.3 0.0
AMP 0.0 2.4 71.4 23.8 2.4 97.6 7.1 1.7
CTX 0.0 2.4 97.6 0.0 0.0 100 0.0 0.0
CFX 0.0 2.4 81.0 19.0 0.0 100 2.3 0.0
CHL 0.0 0.0 97.6 2.4 0.0 100 2.3 0.0
CIP 0.0 0.0 100 0.0 0.0 100 0.0 0.0
CLAR 0.0 4.8 71.4 23.8 0.0 100 16.7 0.0
COT 0.0 0.0 97.6 2.4 0.0 100 0.0 0.0
LVX 0.0 0.0 100 0.0 0.0 100 0.0 0.0
MPM 0.0 2.4 95.2 2.4 0.0 100 0.0 0.0
RIF 0.0 0.0 95.2 4.8 0.0 100 0.0 0.0
TET 0.0 21.4 76.2 2.4 0.0 100 0.0 0.0
Total 0.2 3.2 89.1 7.7 0.0 99.6 2.6 0.2
AMX/CLV, amoxicillin–clavulanate; AMP, ampicillin; CTX, cefotaxime; CFX, cefuroxime; CHL, chloramphenicol; CIP,
ciprofloxacin; CLAR, clarithromycin; COT, co-trimoxazole; LVX, levofloxacin; MPM, meropenem; RIF, rifampicin; TET,
tetracycline.
Table 2 Distribution of the differences in the MICs of 12 antimicrobial agents against 58 strains of S. pneumoniae, and
discrepancies in the clinical categories using the WIDER I system and microdilution (reference method)
% isolates for which the differences in the MICs are
Antimicrobial
agents  2 1 0 þ1 þ 2
% Agreement
(1 log2)
% Errors
Minor
AMX/CLV 1.7 0.0 93.1 5.2 0.0 98.3 3.4
CTX 0.0 6.9 87.9 5.2 0.0 100 0.0
CFX 1.7 3.4 93.1 1.7 0.0 98.3 3.4
CHL 0.0 8.6 91.4 0.0 0.0 100 1.7
COT 1.7 12.1 86.2 0.0 0.0 98.3 0.0
ER 0.0 1.7 96.6 1.7 0.0 100 1.7
LVX 0.0 3.4 91.4 5.2 0.0 100 8.6
MPM 0.0 1.7 81.0 17.2 0.0 100 1.7
PEN 0.0 0.0 96.6 3.4 0.0 100 0.0
RIF 0.0 0.0 100 0.0 0.0 100 0.0
TET 0.0 1.7 89.7 8.6 0.0 100 3.4
VAN 0.0 8.6 79.3 12.1 0.0 100 0.0
Total 0.4 4.0 90.5 5.0 0.0 99.7 2.2
AMX/CLV, amoxicillin–clavulanate; CTX, cefotaxime; CFX, cefuroxime; CHL, chloramphenicol; COT, co-trimoxazole; ER,
erythromycin; LVX, levofloxacin; MPM, meropenem; PEN, penicillin; RIF, rifampicin; TET, tetracycline; VAN,
vancomycin.
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studies including strains of H. influenzae and S.
pneumoniae with well characterized mechanisms of
resistance to b-lactams (b-lactamase production,
alterations in penicillin-binding proteins), quino-
lones (mutations in the gyrA or parC genes) and
macrolides (modifying enzymes, target alteration)
are underway in order to evaluate the capability of
the WIDER I system to detect the susceptibility or
resistance of these strains to clinically relevant
antimicrobial agents and to determine the feasi-
bility of shorter incubation times.
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